EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A novel cabozantinib formulation with improved safety and bioavailability: preclinical validation in rats

Shangwei Qin, Yu Zhang, John Duan, George Kraft, Joanne Bowen

Cancer Chemotherapy and Pharmacology · 14.03.2026 · 96 (1)

DOI: 10.1007/s00280-026-04875-z ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 14.03.2026. Verfasst von Shangwei Qin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hangzhou Handa Pharmaceutical Technology Co., Ltd., Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Pyridines, Anilides, Protein Kinase Inhibitors. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Handa Pharmaceuticals, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridinesAnilidesProtein Kinase InhibitorsAnimalsBiological AvailabilityMaleRatsRats, WistarArea Under CurveDose-Response Relationship, DrugTandem Mass SpectrometryDrug Evaluation, Preclinical

Stichwörter der Autor:innen

BioavailabilityCabozantinibGastrointestinal toxicityPharmacokineticsPreclinical

Substanzen

PyridinescabozantinibAnilidesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Hangzhou Handa Pharmaceutical Technology Co., Ltd., Hangzhou, Zhejiang, China.
  • Handa Pharmaceuticals, Inc., Tainan, Taiwan.
  • Handa Pharmaceuticals, Inc., California, USA. george.kraft@handapharma.com.
  • School of Biomedicine, The University of Adelaide, Adelaide, Australia.

Förderung

  • Handa Pharmaceuticals, Inc.

Zitieren

APA

Qin, S., Zhang, Y., Duan, J., Kraft, G., & Bowen, J. (2026). A novel cabozantinib formulation with improved safety and bioavailability: preclinical validation in rats. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04875-z

Vancouver

Qin S, Zhang Y, Duan J, Kraft G, Bowen J. A novel cabozantinib formulation with improved safety and bioavailability: preclinical validation in rats. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04875-z

BibTeX
@article{Qin2026,
  author = {Qin, Shangwei and Zhang, Yu and Duan, John and Kraft, George and Bowen, Joanne},
  title = {A novel cabozantinib formulation with improved safety and bioavailability: preclinical validation in rats},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2026},
  volume = {96},
  number = {1},
  doi = {10.1007/s00280-026-04875-z}
}
Kostenlos starten →